The law, slated to take effect in September, requires health plans to cover the treatment given by in-network providers, not ...

NEW YORK – The US Food and Drug Administration on Wednesday granted accelerated approval to Dizal's oral EGFR inhibitor Zegfrovy (sunvozertinib) as a treatment for patients with locally advanced or ...

The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.

The study will use a companion lipid biomarker test to identify those with a poor prognosis who are potential best responders.

D Molecular Therapeutics said it is streamlining operations to offset expected expenses as it accelerates the timelines for its Phase III trials.

The study also included older children and found the best outcomes in patients between 5 years and 8 years old.

Using 400 real-world patient cases, the CARE platform correctly classified 99.5 percent of cases according to NCCN guidelines ...

NEW YORK – Iksuda Therapeutics on Monday said it will expand an ongoing Phase I trial of the HER2-targeted antibody-drug conjugate (ADC) IKS014 in solid tumors to US sites. The Newcastle, ...

The firm hopes that ETX-636's dual mechanism inhibiting mutant PI3Kα will give it an edge over competing products on the market.

NEW YORK – Adagene said on Tuesday that Sanofi has made a $25 million investment in the company to support a clinical trial of the anti-CTLA-4 agent muzastotug and exercised its option under their ...

Precision Medicine Online and My Gene Counsel have partnered since 2019 on the "Genetic Testing Challenges" series to highlight real-world issues medical professionals are encountering as genetic ...

NEW YORK – Rutgers New Jersey Medical School has rolled out blood testing for lipoprotein (a), a biomarker associated with cardiovascular disease risk, as part of routine care at another hospital site ...